Novartis deal sees Avidity (RNA) director dispose stock and options
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Avidity Biosciences director Tamar Thompson reported disposing of all her Avidity equity in connection with the company’s merger with Novartis. Footnotes state that her common stock, including shares underlying previously reported restricted stock units, was transferred to the issuer under the merger agreement, and her stock options were cancelled in exchange for cash equal to the merger consideration of $72.00 per share minus each option’s exercise price. Following these issuer dispositions on February 27, 2026, her reported holdings of both common stock and options are shown as zero.
Positive
- None.
Negative
- None.
Insider Trade Summary
5 transactions reported
Mixed
5 txns
Insider
Thompson Tamar
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Option (Right to Buy) | 10,034 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 13,489 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 22,000 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 22,000 | $0.00 | -- |
| Disposition | Common Stock | 6,692 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 0 shares (Direct);
Common Stock — 0 shares (Direct)
Footnotes (1)
- The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer. The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price.
FAQ
What did Avidity Biosciences (RNA) director Tamar Thompson report on this Form 4?
Tamar Thompson reported disposing of all her Avidity Biosciences equity. Her common stock and stock options were transferred or cancelled in connection with the merger with Novartis, leaving her with zero reported common shares and options after the transactions.
How were Tamar Thompson’s Avidity Biosciences stock options treated in the Novartis merger?
Her Avidity stock options were cancelled under the merger agreement and exchanged for cash. Each option received a payment equal to the merger consideration of $72.00 per share minus its exercise price, reflecting standard cash-out treatment in an all-cash merger.
What happened to Tamar Thompson’s Avidity Biosciences common stock in this filing?
Her common stock, including shares issuable from previously reported restricted stock units, was disposed of to the issuer under the Novartis merger agreement. After this issuer disposition, the Form 4 shows her owning zero shares of Avidity common stock directly.
Does Tamar Thompson still hold any Avidity Biosciences securities after these transactions?
According to the reported totals, she holds no Avidity securities after the merger-related dispositions. The Form 4 shows zero shares of common stock and zero stock options remaining following the February 27, 2026 transactions disclosed in the filing.
What merger agreement is referenced in Tamar Thompson’s Avidity Biosciences Form 4?
The filing references an Agreement and Plan of Merger dated October 25, 2025 among Novartis AG, Ajax Acquisition Sub, Inc., an indirect Novartis subsidiary, and Avidity Biosciences. The reported stock and option dispositions occurred pursuant to this merger agreement.
Atrium Therapeutics, Inc